CureVac N.V. (5CV.F)
3.82
-0.02 (-0.42%)
At close: Jan 14, 2025, 5:15 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 856.85M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.47 |
| PE Ratio (ttm) | 8.13 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 9,201 |
| Avg. Volume (20D) | 26,606 |
| Open | 3.95 |
| Previous Close | 3.84 |
| Day's Range | 3.82 - 4.04 |
| 52-Week Range | 2.06 - 4.95 |
| Beta | undefined |
About 5CV.F
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 cli...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2020
Employees 999
Stock Exchange XETRA
Ticker Symbol 5CV.F
Website https://www.curevac.com